Accuray cyberknife® robotic radiotherapy platform could significantly improve survival in early-stage breast cancer patients

Sunnyvale, calif., oct. 25, 2021 /prnewswire/ -- accuray incorporated (nasdaq: aray) announced today that a study published in frontiers in oncology  found early-stage breast cancer patients could experience significant improvements in survival if treated with accelerated partial breast irradiation (apbi) delivered using the accuray cyberknife ® robotic radiotherapy platform.
ARAY Ratings Summary
ARAY Quant Ranking